Answers are grounded in this paper and cite their sources.
This study elucidates the potential mechanisms by which Empa slows the progression of renal fibrosis in nondiabetic CKD. By reducing the number of M2 macrophages and inhibiting signal transduction in both pro-inflammatory and fibrotic pathways, Empa modulates the intercellular communication network in renal cells, offering a promising therapeutic strategy for CKD management.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: